ONCOSEQ DNALAB HOMOLOGICAL RECOMBINATION DEFICIENCY PANEL (HRD)

(15 GENE)

HRD testing can detect germline and somatic mutations in homologous recombination repair genes, including BRCA1 and BRCA2. Looking at both the tumor and the germline allows us to identify high-risk ovarian cancer patients in family members and learn whether there are variants in the tumor that may cause homologous recombination deficiency and plan targeted treatment using PARP inhibitors. HRD testing is recommended in all patients with ovarian cancer and triple-negative breast cancer to understand the suitability of using next-generation cancer drugs that are effective in DNA repair defects in PARP inhibitors.